Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. Issue 5 (23rd October 2015)

• Record Type: Journal Article
• Authors: Leo, Joyce M; Kalloger, Steve E; Peixoto, Renata D; Gale, Nadia S; Webber, Douglas L; Owen, David A; Renouf, Daniel; Schaeffer, David F
• Is Part Of: Journal of clinical pathology. Volume 69:Issue 5(2016)
• Page Start: 431
• Page End: 439
• Publication Date: 2015-10-23
• Subjects: HISTOPATHOLOGY -- CANCER -- PANCREAS -- CHEMOTHERAPY; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2015-203337
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Background: Ampullary carcinomata (AC) can be separated into intestinal (IT) or pancreatobiliary (PB) subtypes. Although morphological, immunohistochemical and molecular differentiation of IT and PB have been well documented; the prognostic significance of histological subtype and whether patients with either subtype benefit from differential chemotherapeutic regimens remains unclear. Methods: As part of a larger cohort study, patients who underwent resection for AC or pancreatic ductal adenocarcinoma (PDAC) were retrospectively identified. Clinicopathological covariates and outcome were obtained and MUC1, MUC2, CDX2 and CK20 were assessed with immunohistochemistry. Results: Of 99 ACs, the resultant immunophenotypes indicated 48% and 22% were IT and PB, respectively. Thirty (30%) cases were quadruple negative (QN). Within the PDAC cohort (N=257), the most prevalent immunophenotype was QN (53%). Subsequently, all QN ACs were classified as PB immunohistochemically yielding 47.5% and 52.5% classified as IT and PB, respectively. Involved regional lymph nodes and elevated T-stage were significantly associated with PB compared with IT AC (p=0.0032 and 0.0396, respectively). Progression-free survival revealed inferior survival for PB versus IT AC (p=0.0156). Conclusions: AC can be classified into prognostic groups with unique clinicopathological characteristics using immunohistochemistry. Immunophenotypical similarity of PB and PDAC suggests that treatment regimens similar to those used in PDAC should be explored.